RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

Trial's Objective Response Rate Endpoint Already Achieved RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase

Related Keywords

Texas ,United States ,France ,Houston ,America ,Izabela Tworowska ,Julien Dodet ,Ebrahim Delpassand ,Mike Sinclair ,Radiomedix Inc ,Spica Center ,Objective Response Rate Endpoint Already ,Orano Med ,Chief Executive Officer ,Targeted Alpha Emitter Therapy ,North America ,Medical Officer ,Gefallene Big Techs ,Radiomedix ,Erano ,Omplete ,Patient ,Enrolment ,Hase ,Trial ,Argeted ,Lpha ,Emitter ,Lphamedix ,Neuroendocrine ,Cancers ,